An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED)

An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients

A study to determine the safety and efficacy of an investigational drug in patients with obesity.

Inclusion Criteria:

• Obese patients with a body mass index between 30kg/m2 and 43 kg/m2, inclusive (BMI between 27 kg/m2 and 43kg/m2, inclusive for those with obesity-related comorbidities including hypertension, dyslipidemia and sleep apnea).

Exclusion Criteria:

• Patients with serious or unstable current or past medical conditions.